Navigation Links
Respironics, Inc. Completes Voluntary Recall Notification of a Limited Number of Trilogy 100 Ventilators

MURRYSVILLE, Pa., Jan. 12, 2012 /PRNewswire/ -- Respironics, Inc. announced today that it has completed notifying customers of a voluntary recall of 52 Trilogy Model 100 ventilators in the United States and has confirmed that 51 have already been removed from use. The recall was initiated on October 11, 2011 to address a manufacturing issue that may have affected these ventilators. Respironics received no reports of ventilator malfunctions, failures or injuries related to this issue.  

The Trilogy 100 ventilator provides portable volume and pressure support ventilation for adult and pediatric use in both invasive and noninvasive applications. Other Trilogy ventilator models distributed in the United States, the Trilogy 200 and 202, were not affected by this recall.

An internal Respironics data review found that when the blower assemblies of the recalled ventilators were manufactured, the force used to press the impeller onto the blower motor shaft was less than the specified minimum force. This could result in the impeller moving up the motor shaft and coming in contact with the inside of the blower housing. If this were to occur, it could cause noise, the sounding of an inoperative ventilator alarm, or a blower failure. In the event of a blower failure, the ventilator would stop delivering therapy and a high priority alarm would sound to alert the caregiver to immediately respond. Failure to respond could result in the potential for harm or death of a ventilator dependent patient.

Respironics began notifying its United States distributors, providers, sales personnel and customers of the recall by telephone on October 11, 2011.  Although the Respironics customers who received the affected units have already confirmed receipt of our notice, customers who have questions about the recall may contact Respironics Customer Service at 1-877-387-3311. Please see attached serial number list of affected units that were recalled.

Respironics notified the U.S. Food & Drug Administration (FDA) of its decision to voluntarily recall the affected product on October 7, 2011. Any adverse reactions experienced with the use of this product should be reported to the FDA's MedWatch Program by phone at 1-800-FDA-1088, by fax at 1-800-FDA-0178, by mail at MedWatch, HF-2, FDA, 5600 Fishers Lane, Rockville, MD 20852-9787, or on the MedWatch website at Adverse reactions and/or quality problems should also be reported to Respironics at 1-877-387-3311. 

Serial Numbers of Domestic Devices RecalledTV111021835








































SOURCE Respironics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Quest Diagnostics Completes Acquisition of S.E.D. Medical Laboratories
2. Elevation Pharmaceuticals Completes $30 Million Series B Financing to Advance Aerosol COPD Therapy
3. Weikang Bio-technology Group, Inc. Completes HQ Relocation After Purchasing Building for $14 Million and Answers Questions About its Third Quarter Financials
4. Orexigen® Therapeutics Completes Public Offering of Common Stock and Warrants to Purchase Common Stock
5. Valeant Pharmaceuticals Completes Acquisition of iNova
6. Valeant Pharmaceuticals Completes Acquisition of Dermik
7. Vermillion Completes the Acquisition of Correlogic Systems Ovarian Cancer Diagnostics Business
8. Perceptive Informatics Completes Over 500 System Integrations as the Biopharma Industry Continues to Adopt Seamless eClinical Solutions
9. Sotera Wireless Completes $12.2 Million Series D Financing, Signs Agreement with Cerner
10. Concord Medical Completes its Twelfth Annual Academic Conference
11. China Health Resource Completes Key Research Project - New Proprietary Product Lines
Post Your Comments:
(Date:11/26/2015)... Nederland, November 26, 2015 ... Een nieuwe aanpak combineert immunotherapie met Bremachlorin-photodynamische ... ) --> ...      (Photo: ) ... Universitair Medisch Centrum (LUMC) blijkt ...
(Date:11/26/2015)... -- 3D bioprinting market is expected to ... report by Grand View Research Inc. Rising prevalence of chronic ... transplantation is expected to boost the market growth, as 3D ... --> 3D bioprinting market is expected to ... report by Grand View Research Inc. Rising prevalence of chronic ...
(Date:11/26/2015)... DUBLIN , November 26, 2015 ... has announced the addition of the  ... in the Global Cell Surface Testing ... Opportunities" report to their offering.  ... the addition of the  "2016 Future ...
Breaking Medicine Technology:
(Date:11/27/2015)... (PRWEB) , ... November 27, 2015 , ... ... of the well-respected Microsoft Dynamics SL User Group (MSDSLUG). Recognized as Microsoft’s official ... independent group of Microsoft Dynamics SL software users, partners, industry experts and representatives. ...
(Date:11/27/2015)... ... November 27, 2015 , ... The moment ... itself for not only fulfilling the needs of advisers and clients but going ... price and providing top-tier customer service. However, there's always room for improvement, which ...
(Date:11/27/2015)... ... 27, 2015 , ... CBD College is proud to announce that ... awarded accreditation to its Diagnostic Medical Sonography program. CBD College is honored to join ... twelve colleges and universities in the state of California make the cut. CBD College ...
(Date:11/27/2015)... (PRWEB) , ... November 27, 2015 , ... Dr. ... Medical Associates, Inc. and Dr. Tucker Bierbaum with Emergency Medicine at St., ... observed that both STEMI and Sepsis conditions present in similar ways and require time-critical ...
(Date:11/27/2015)... ... , ... Indosoft Inc., developer and distributor of the world-class ... (Long Term Support) into its Q-Suite 5.10 product line. , Making the change ... version of Asterisk that will receive not only security fixes, but feature and ...
Breaking Medicine News(10 mins):